An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
← catalyst calendarNCT06832410 · readout in 29 d
Sponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
10estimated
Sites
7
Countries
Canada, Saudi Arabia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-31 | actual | When the study began enrolling |
| Primary completion | 2026-09-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-17 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Type 1 Diabetes
- Kidney Transplant
Intervention
- Biological: Biological/Vaccine — also filed as Zimislecel, Formerly known as STx-02
Primary outcome
what the primary-completion date above is the date OFProportion of Participants who are Insulin Independent
measured At 1 year After VX-880 infusion
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed